Cost-effectiveness analysis of universal newborn screening for medium chain acyl-CoA dehydrogenase deficiency in France

Table 2 Cost-effectiveness of the introduction of MCADD newborn screening in France

Description of results	Introduction of MCADD screening	Introduction of MCADD screening combined with switch to MS/MS for PKU screening*
Effectiveness
Deaths averted	5.47	5.47
Mild neurological sequelae prevented	1.37	1.37
Severe neurological sequelae prevented	1.37	1.37
LY gained	128	128
QALY gained	138	138
Costs
Costs of testing alone^† (€)	3 187 660	1 742 702
Net incremental costs of screening ^‡(€)	2 493 055	1 048 097
Incremental cost-effectiveness ratios
€ per LY gained	19 478	8 189
€ per QALY gained	18 033	7 581

* The cost of the current technology PKU screening test (€1.76) was subtracted from that of the MS/MS screening test. The incremental effectiveness was the same as that for the introduction of MCADD screening alone as it was assumed that the performance of MS/MS for PKU screening was similar to that of the current technology; see text.
^† Includes the cost of screening and confirmation tests.
‡ Includes the cost of testing as well as the cost of follow-up and of management of diagnosed patients.

ISSN: 1471-2431